Exploring Mechanism of Action of Dietary Fibre on the Gut Microbiota and Metabolites

NCT ID: NCT05906589

Last Updated: 2024-12-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-25

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cancer patients receiving pelvic radiotherapy suffer side effects to the intestine, including diarrhoea and occasionally rectal bleeding, often worsened by chemoradiation. Many pelvic radiotherapy patients receive a form of dietary fibre, psyllium husk, to manage their diarrhoeal symptoms. There is evidence in mice that dietary fibre supplementation can improve tumour response and reduce normal tissue side effects caused by radiation. If this were to be confirmed in humans, it would be a major advance in patient treatment. The investigators will conduct a study in healthy subjects to assess mechanisms and response to dietary fibre.

The investigators will conduct a within-subject diet intervention study on healthy older adults (\>60 years old) to determine if a subset of the population are responders to dietary fibre manipulation, using inulin with or without psyllium. This will allow assessment of the physiological impact of dietary fibre. Participants will receive placebo, inulin, or psyllium plus inulin in random order (6 possible combinations) for two weeks each with two-week washout periods.

Baseline faecal microbial activity, short chain fatty acid (SCFA) concentrations, and habitual fibre intake, determined by dietary questionnaires/food diaries will be used to identify individuals in whom dietary fibre manipulation might have a positive impact. Individuals who respond to dietary fibre supplementation may be found to have elevated levels of some SCFAs and significantly increased relative abundance of certain microbiota. Dietary parameters, bacterial relative abundance and SCFA levels will be correlated with plasma cytokine levels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Of all patients receiving radiotherapy for cancer in 2018 and 2019, 28.6% were treated for a pelvic malignancy. The dose of radiotherapy necessary to cure the tumour often causes side effects in the surrounding healthy tissues, which can significantly impact the patients quality of life. Chemoradiation, the addition of chemotherapy to radiotherapy, improves tumour cure rates by radiosensitising the tumour, but at the expense of worsened normal tissue effects. Most patients over 80 years are unable to tolerate chemoradiation. With an aging population, there is an urgent clinical need to find alternatives to chemoradiation.

A difference in the composition and diversity of the gut microbiota has been found in responders versus non-responders to immunotherapy and in patients experiencing different levels of toxicities following radiotherapy. This indicates that the microbiota could be used to predict, prevent, or treat radiation enteropathy. An often-found side effect in pelvic radiotherapy patients is diarrhoea. Many pelvic radiotherapy patients receive a form of dietary fibre, known as psyllium husk (ispaghula husk or FybogelTM) to manage their diarrhoeal symptoms. Dietary fibres like psyllium and inulin are non-digestible carbohydrates found in fruits, vegetables, whole grains and legumes. They are anaerobically fermented by the gut bacteria, producing SCFAs, including acetate, propionate, and butyrate. SCFAs are the main performers in the interplay between diet, microbiota and health, and have anti-inflammatory and also anti-tumorigenic properties.

A high intake of dietary fibre is proven to decrease the risk of type 2 diabetes, colon cancer and cardiovascular disease by reducing the digestion and absorption of macronutrients and decreasing the contact time of carcinogens with the intestinal lumen. There is emerging evidence that the inclusion of dietary fibre supplements in the diet could modify the tumour response to radiotherapy. If confirmed in humans, this would be a major advance in patient treatment.

In a mouse model of colitis, exhibiting similar acute symptoms to those due to radiotherapy, the addition of psyllium in the diet reduced colonic inflammation and protected intestinal tight junctions. This prevented penetration of luminal inflammatory molecules through the gut wall. In a similar model system, psyllium reduced the severity of colitis in C57BL/6 specific pathogen-free and germ-free mice, via microbiota-dependent and independent mechanisms.

Inulin, another dietary fibre, is rapidly fermented in the proximal large intestine. Here, it selectively increases the growth of the butyrate producer Faecalibacterium prausnitzii and Bifidobacterium spp.. Bifidobacteria are associated with anti-tumour effects and augmented dendritic cell function leading to increased Cytotoxic T-cell (CD8+) priming and accumulation in the tumour microenvironment.

The investigators found promising preliminary data in our mouse studies, indicating that psyllium with inulin enhances tumour control. Immunodeficient mice fed a 10% inulin diet had an improved tumour control following 6 gray (Gy) ionising radiation. Immunocompetent mice showed a delayed tumour growth when receiving psyllium plus inulin when compared to a normal or low fibre diet, accompanied by significantly increased tumour infiltration of cytotoxic T cells. Psyllium plus inulin also significantly increased the percentage of intestinal remaining after 14 Gy compared to a low fibre diet or psyllium alone. A psyllium plus inulin diet also modified intestinal immunity, particularly B cells. Furthermore, in mouse bladder cancer cell UPPL 1591-derived allografts, CD8+ (cytotoxic) T cells scored higher for psyllium and psyllium plus inulin than psyllium plus resistant starch. However, compared to humans, inbred mice are genetically more similar and are held in controlled environmental conditions, so humans are likely to demonstrate more variability in response to dietary fibre intervention.

The investigators will study a group of human participants to assess tolerance and responses to inulin and psyllium plus inulin, in terms of intestinal side effects, significant alterations in the microbiota, levels of SCFAs in plasma and faeces, and plasma inflammatory cytokines. The investigators will also investigate whether responders and non-responders within the study can be identified from baseline dietary information and/or microbial activity (based on faecal SCFA measurements), as an individual's current diet will influence their response to dietary fibre modification.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psyllium Inulin

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dietary fibre Dietary fiber Gut microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

The participants will be randomly allocated to one of the 6 different intervention combinations for the supplements ((A) placebo; (B) inulin; (C) psyllium plus inulin) with the same number of participants in each of the combinations.

There are 6 possible combinations:

* A \> B \> C
* B \> A \> C
* C \> B \> A
* A \> C \> B
* C \> A \> B
* B \> C \> A
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators
The study will be double blind, meaning both the investigator and the participants will not know if the participants are receiving inulin, psyllium plus inulin or the placebo. However, there is some difference in the consistency of the powders. The supplements will be labelled A, B and C by an independent party otherwise not involved in the study, and the investigator and participants will not know which supplement is which letter during the study period.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inulin

The participant will be asked to administer the provided doses of 8g inulin twice daily.

Group Type EXPERIMENTAL

Inulin

Intervention Type DIETARY_SUPPLEMENT

The participant will take inulin twice daily over a 14 day period.

Inulin + psyllium

The participant will be asked to administer the provided doses of 8g inulin + 3.5g psyllium twice daily.

Group Type EXPERIMENTAL

Inulin

Intervention Type DIETARY_SUPPLEMENT

The participant will take inulin twice daily over a 14 day period.

Psyllium

Intervention Type DIETARY_SUPPLEMENT

The participant will take psyllium twice daily over a 14 day period.

Maltodextrin

The participant will be asked to administer the provided doses of 8g maltodextrin twice daily.

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

The participant will take maltodextrin twice daily over a 14 day period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inulin

The participant will take inulin twice daily over a 14 day period.

Intervention Type DIETARY_SUPPLEMENT

Psyllium

The participant will take psyllium twice daily over a 14 day period.

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

The participant will take maltodextrin twice daily over a 14 day period.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ispaghula husk

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>60 years old

Exclusion Criteria

* Oral antibiotic use (within the past 3 months due to impact on gut microbiota).
* Anti-coagulants (Warfarin).
* Carbamazepine (epilepsy)
* Digoxin (heart conditions)
* Mesalazine (gut problems)
* Regular use of anti-constipation medication/laxatives.


* Food allergies, self-reported food sensitivity or intolerance.
* Type 1 or Type 2 diabetes.
* Coeliac disease or gluten intolerance.
* Metformin intake.
* Bowel obstruction
* Muscle weakness of the bowel
* Phenylketonuria.


* Anyone with unsuitable veins for blood sampling.
* Anyone with chronic constipation (\>3 days without defaecation).
* Anyone who is unable to fluently speak, read and understand English.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Aberdeen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anne E Kiltie, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Aberdeen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rowett Institute

Aberdeen, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Merel A van den Haak, Msc

Role: CONTACT

Phone: 01224438756

Email: [email protected]

Anne E Kiltie, Prof

Role: CONTACT

Phone: 01224 438651

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Merel A van den Haak, Msc

Role: primary

Anne E Kiltie, Prof

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Wang L, Wang X, Zhang G, Ma Y, Zhang Q, Li Z, Ran J, Hou X, Geng Y, Yang Z, Feng S, Li C, Zhao X. The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review. Radiat Oncol. 2021 Sep 25;16(1):187. doi: 10.1186/s13014-021-01899-y.

Reference Type BACKGROUND
PMID: 34563216 (View on PubMed)

Bishehsari F, Engen PA, Preite NZ, Tuncil YE, Naqib A, Shaikh M, Rossi M, Wilber S, Green SJ, Hamaker BR, Khazaie K, Voigt RM, Forsyth CB, Keshavarzian A. Dietary Fiber Treatment Corrects the Composition of Gut Microbiota, Promotes SCFA Production, and Suppresses Colon Carcinogenesis. Genes (Basel). 2018 Feb 16;9(2):102. doi: 10.3390/genes9020102.

Reference Type BACKGROUND
PMID: 29462896 (View on PubMed)

Carretta MD, Quiroga J, Lopez R, Hidalgo MA, Burgos RA. Participation of Short-Chain Fatty Acids and Their Receptors in Gut Inflammation and Colon Cancer. Front Physiol. 2021 Apr 8;12:662739. doi: 10.3389/fphys.2021.662739. eCollection 2021.

Reference Type BACKGROUND
PMID: 33897470 (View on PubMed)

Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. Adv Immunol. 2014;121:91-119. doi: 10.1016/B978-0-12-800100-4.00003-9.

Reference Type BACKGROUND
PMID: 24388214 (View on PubMed)

Kaczmarczyk MM, Miller MJ, Freund GG. The health benefits of dietary fiber: beyond the usual suspects of type 2 diabetes mellitus, cardiovascular disease and colon cancer. Metabolism. 2012 Aug;61(8):1058-66. doi: 10.1016/j.metabol.2012.01.017. Epub 2012 Mar 7.

Reference Type BACKGROUND
PMID: 22401879 (View on PubMed)

Olopade FA, Norman A, Blake P, Dearnaley DP, Harrington KJ, Khoo V, Tait D, Hackett C, Andreyev HJ. A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy. Br J Cancer. 2005 May 9;92(9):1663-70. doi: 10.1038/sj.bjc.6602552.

Reference Type RESULT
PMID: 15856043 (View on PubMed)

Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell. 2018 Apr 9;33(4):570-580. doi: 10.1016/j.ccell.2018.03.015.

Reference Type RESULT
PMID: 29634945 (View on PubMed)

Reis Ferreira M, Andreyev HJN, Mohammed K, Truelove L, Gowan SM, Li J, Gulliford SL, Marchesi JR, Dearnaley DP. Microbiota- and Radiotherapy-Induced Gastrointestinal Side-Effects (MARS) Study: A Large Pilot Study of the Microbiome in Acute and Late-Radiation Enteropathy. Clin Cancer Res. 2019 Nov 1;25(21):6487-6500. doi: 10.1158/1078-0432.CCR-19-0960. Epub 2019 Jul 25.

Reference Type RESULT
PMID: 31345839 (View on PubMed)

Ogata M, Ogita T, Tari H, Arakawa T, Suzuki T. Supplemental psyllium fibre regulates the intestinal barrier and inflammation in normal and colitic mice. Br J Nutr. 2017 Nov;118(9):661-672. doi: 10.1017/S0007114517002586.

Reference Type RESULT
PMID: 29185927 (View on PubMed)

Llewellyn SR, Britton GJ, Contijoch EJ, Vennaro OH, Mortha A, Colombel JF, Grinspan A, Clemente JC, Merad M, Faith JJ. Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice. Gastroenterology. 2018 Mar;154(4):1037-1046.e2. doi: 10.1053/j.gastro.2017.11.030. Epub 2017 Nov 23.

Reference Type RESULT
PMID: 29174952 (View on PubMed)

Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br J Nutr. 2009 Feb;101(4):541-50. doi: 10.1017/S0007114508019880. Epub 2008 Jul 1.

Reference Type RESULT
PMID: 18590586 (View on PubMed)

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.

Reference Type RESULT
PMID: 26541606 (View on PubMed)

Then CK, Paillas S, Wang X, Hampson A, Kiltie AE. Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation. BMC Biol. 2020 Aug 19;18(1):102. doi: 10.1186/s12915-020-00836-x.

Reference Type RESULT
PMID: 32811478 (View on PubMed)

Walker AW, Ince J, Duncan SH, Webster LM, Holtrop G, Ze X, Brown D, Stares MD, Scott P, Bergerat A, Louis P, McIntosh F, Johnstone AM, Lobley GE, Parkhill J, Flint HJ. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011 Feb;5(2):220-30. doi: 10.1038/ismej.2010.118. Epub 2010 Aug 5.

Reference Type RESULT
PMID: 20686513 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

501

Identifier Type: -

Identifier Source: org_study_id